Follow-up of 20 patients with idiopathic pulmonary fibrosis treated with Nintedanib

##plugins.themes.bootstrap3.article.sidebar##

PDF (Español (España))
Published Oct 25, 2022

##plugins.themes.bootstrap3.article.main##

ALVARO UNDURRAGA
Instituto Nacional del Tórax, Santiago

Abstract

A compassionate observational follow-up study of 20 patients with Idiopathic Pulmonary Fibrosis treated with Nintedanib is presented, showing that Nintedanib is a generally well-tolerated drug, with no serious adverse effects, that grants a longer survival in real-life patients

##plugins.themes.bootstrap3.article.details##

Keywords.

Humans, Nintedanib, Idiopathic Pulmonary Fibrosis, Follow-up studies

Issue
Vol. 38 No. 3 (2022)
Section
ORIGINAL ARTICLE
Copyright.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

UNDURRAGA , A. (2022). Follow-up of 20 patients with idiopathic pulmonary fibrosis treated with Nintedanib. Revista Chilena De Enfermedades Respiratorias, 38(3), 160–167. Retrieved from https://revchilenfermrespir.cl/index.php/RChER/article/view/1073